Overview of angiogenesis during tumor growth

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 161-168

  Ribatti, Domenico ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

angiogenesis; angiogenic switch; endothelial precursor cells; hematopoietic cells; hypoxia; inflammatory cells; pericytes; tumor progression; vascular cooption

Indexed keywords

EID: 72849130538     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_14     Document Type: Chapter

References (82)

1. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor fraction responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
3. McAuslan BR, Hoffman H. Endothelium stimulating factor from Walker carcinoma cells. Relation to tumor angiogenic factor. Exp Cell Res 1979; 119: 181-190.
4. Weiss JB, Brown RA, Kumar S, et al. An angiogenic factor isolated from tumours: a potent low-molecular weight compound. Brit J Cancer1979; 40: 493-496.
5. Fenselau A, Kaiser D, Wallis K. Nucleoside requirements for the in vivo growth of bovine aortic endothelial cells. J Cell Physiol 1981; 108: 375-384.
6. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999; 1: 293-302.
7. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-C970.
8. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antian-giogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883-893.
9. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
10. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1638-1683.
11. Black WC, Welch HG. Advances in diagnostic imaging and over-estimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328: 1237-1243.
12. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
13. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151: 1417-1423.
14. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199.
15. Hanahan D. Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant unsylin/simian virus 40 oncogene. Nature 1985; 315: 115-122.
16. Ribatti D, Nico B, Crivellato E, et al. The history of the angio-genic switch comcept. Leukemia 2007; 21: 44-52.
17. Burri PH, Djonov V. Intussusceptive angiogenesis, the alternative to capillary sprouting. Mol Aspects Med 2002; 23: S1-S27.
18. Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 1996; 51: 260-272.
19. Djonov V Andres AC, Ziemiecki A. Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Techn 2001; 52: 182-189.
20. Patan, S, Tanda S, Roberge S, et al. Vascular morphogenesis and remodeling in a human tumor xenograft: blood vessel formation and growth after ovariectomy and tumor implantation. Circ Res 2001; 89: 732-739.
21. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angio-genesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2002; 60: 1388-1393.
22. Turner HE, Nagy Z, Gatter KC, et al. Angiogenesis in pituitary adenomas and in the normal pituitary gland. J Clin Endocrinol Metab 2000; 85: 1159-1162.
23. Sterinberg F, Rohrborn HJ, Otto T, et al. NIR reflection measurements of hemoglobin and cytochrome da3 in healthy tissue and tumors. Correlation to oxygen consuption: preclinical and clinical data. Adv Exp Med Biol 1997; 428: 69-77.
24. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
25. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999; 159: 391-400.
26. Holash J, Wiegand SJ, Yancopoulos GF. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-5362.
27. Yancopoulos GD, Davis S, Gale NW, et al. Vascular specific growth factors and blood vessels formation. Nature 2000; 407: 242-248.
28. Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simulatenous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002; 109: 777-785.
29. Kusters B, Leenders WP, Wesseling P, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002; 62: 341-345.
30. Dvorak H. Tumors: wounds that not heal. Similarities between tumor stroma generation and wound healing. New Engl J Med 1986; 315: 1650-1659.
31. Ribatti D, Nico B, Crivellato E, et al. The structure of the vascular networks of tumors. Cancer Letters; 2007; 248: 18-23.
32. Jain RK, Munn LL. Leaky vessels? Call Angl Nat Med 2000; 6: 131-132.
33. Stromblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6: 462-468.
34. Neri D, Caremolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997; 15: 1271-1275.
35. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol 1995; 5: 69-74.
36. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202.
37. Madden SL, Cook BP, Nacht M, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165: 601-608.
38. Parker BS, Argani P, Cook BP, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64: 7857-7866.
39. Van Beijnum J, Dings RP, van der Linden E, et al. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-2348.
40. Levy A P, Levy NS, Wegner S, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333-13340.
41. Plate KH, Breier G, Widch HA, et al. Vascular endothelial growth factor is a potent tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-848.
42. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angio-genesis. Nature 1992; 359: 843-845.
43. Potgens AJ, Lubsen NH, van Altena MC, et al. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146: 197-209.
44. Claffey KP, Brown LF, Del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172-181.
45. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997; 57: 3860-3864.
46. Semenza GL. Transcriptional regulation by hypoxia-inducible factor-1. Trends Cardiovasc Med 1996; 6: 151-157.
47. Carmeliet P, Dor Y, Herbert JM, Fukumura D, et al. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumor angio-genesis. Nature 1998; 394: 485-490.
48. Abramsson A, Lindblom P, Betshowz C. Endothelial and non-endothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112: 1142-1151.
49. Guo P, Hu B, Gu W, Xu L, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothe-lial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162: 1083-1093.
50. Chae SS, Paik JH, Furneaux H, et al. Requirement for sphin-gosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 2004; 114: 1082-1089.
51. Machein MR, Knedla A, Knoth R, et al. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 2004; 165: 1557-1570.
52. Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and-2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001; 61: 1255-1259.
53. Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003; 63: 3370-3377.
54. Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metal-loproteinase-9 regulates the vascular architecture in neuroblas-toma by promoting pericyte recruitment. Cancer Res 2004; 64: 1675-1686.
55. Spurbeck WW, NG CY, Strom TS, et al. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 2002; 100: 3361-3368.
56. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000; 6: 324-329.
57. Leek RD, Lander RJ, Harris AL, et al. Necrosis correlates with high vascular density and focal macrophages infiltration in invasive carcinoma of the breast. Br J Cancer 1999; 79: 991-995.
58. Bingle L, Brown NJ, Lewis CE. The role of tumor associated macrophages in tumor progression; implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
59. Jenkins DC, Charles IG, Thomsen LL, et al. Role of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995; 92: 4392-4396.
60. Gruber BL, Marchase MJ, Kaw R. Angiogenic factors stimulate mast cell migration. Blood, 86: 2488-2493.
61. Lin E Y, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004; 90: 2053-2058.
62. Ribatti D, Crivellato E, Roccaro AM, et al. Mast cell contribution to angiogenesis related to tumor progression. Clin Exp Allergy 2004; 34: 1660-1664.
63. Kessler DA, Langer RS, Pless NA, et al. Mast cell and tumor angiogenesis. Int J Cancer 1977; 18: 703-709.
64. Starkey JR, Crowle PK, Taubenberger S. Mast cell-deficient W/W mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1998; 42: 48-52.
65. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
66. Ellis LM, Staley CA, Liu W et al. Downregulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 1998; 273: 1052-1057.
67. Tang Y, Kim M, Carrasco D et al. In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res 2005; 65: 8324-8330.
68. Watnick RS, Cheng YN, Rangarajan A, et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-231.
69. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213.
70. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
71. Seftor RB, Seftor EA, Koshikawa N, et al Cooperative interactions of laminin 5 gamma-2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61: 6322-6327.
72. McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how novel, and how significant. Am J Pathol 2000; 156: 383-388.
73. Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000; 97: 14608-14613.
74. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 3964-3972.
75. Takahashi T, Kalka C, Masuda H, et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438.
76. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193-1206.
77. De Palma M, Venneri MA, Roca C, et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9: 789-795.
78. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
79. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med, 7: 1194-1201.
80. Davidoff AM, Ng CY, Brown P, et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001; 7: 2870-2879.
81. Weidner N, Sample JP, Welch WR, et al. Tumor angiogenesis correlates with metastasis in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
82. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.